However, consumers primary reason for taking a GLP-1 was split between: Treating a chronic health condition (38%) Losing weight (30%) Both losing weight and treating a chronic condition (32%) Why it matters: Consumer awareness and interest is growing in GLP-1s, which is increasing alongside actual use
Biology becomes more complex, the placebo effect creeps in, and there may even be unintended long-term consequences
The main federal Wegovy litigation remains focused on gastrointestinal injuries, while NAION-related allegations should be evaluated separately based on medical records, diagnosis, timing, and prescribing history
It could be cancer destroying healthy cells and releasing B12 back to the blood, a bad liver that can no longer store B12, or an increased production of the transport protein haptocorrin, to which blood B12 binds